Efeitos do uso prolongado de meloxicam em equinos hígidos: achados clínicos, laboratoriais, gastroscópicos e eletrocardiográficos

Dinamérico de Alencar Santos Júnior, Caio Victor Damasceno Carvalho, Maynara Kalya Ferreira Lima, E. G. D. Miranda Neto, P. Escodro
{"title":"Efeitos do uso prolongado de meloxicam em equinos hígidos: achados clínicos, laboratoriais, gastroscópicos e eletrocardiográficos","authors":"Dinamérico de Alencar Santos Júnior, Caio Victor Damasceno Carvalho, Maynara Kalya Ferreira Lima, E. G. D. Miranda Neto, P. Escodro","doi":"10.5433/1679-0359.2024v45n4p1047","DOIUrl":null,"url":null,"abstract":"Non-steroidal anti-inflammatory drugs are extensively used in veterinary practice. COX-2 inhibitors are considered to be safer than non-selective inhibitors; however, there are few studies address of their long-term use in equine species. The goal of this study was to identify the possible adverse effects of meloxicam (a preferential COX-2 inhibitor) in healthy horses, administered at a dose of 0.6 mg/kg, orally, once a day, for 28 days. A paired test was performed with seven animals, and the clinical, hematological, biochemical, and gastroscopic parameters, as well as bleeding time, were evaluated in five timepoints and an electrocardiogram at three timepoints. No relevant adverse effects were observed in terms of the parameters evaluated. Significant differences were found in heart rate, AST and P wave duration, segmented neutrophils (%), and the levels of erythrocytes, hemoglobin, hematocrit, and MCH, compared with these parameters at T0; however, no animal manifested clinical alterations. Gastroscopy revealed discrete lesions (Grade 1) in the squamous gastric mucosa on day 14 of treatment in all animals; however, at the end of the study (day 28) these lesions had regressed to grade 0 in three of the horses and remained at grade 1 in the other four animals. Based on these results, we conclude that the use of meloxicam at a daily dose of 0.6 mg/kg, orally, for 28 consecutive days, did not cause relevant adverse effects in healthy horses.","PeriodicalId":21921,"journal":{"name":"Semina: Ciências Agrárias","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Semina: Ciências Agrárias","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5433/1679-0359.2024v45n4p1047","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Non-steroidal anti-inflammatory drugs are extensively used in veterinary practice. COX-2 inhibitors are considered to be safer than non-selective inhibitors; however, there are few studies address of their long-term use in equine species. The goal of this study was to identify the possible adverse effects of meloxicam (a preferential COX-2 inhibitor) in healthy horses, administered at a dose of 0.6 mg/kg, orally, once a day, for 28 days. A paired test was performed with seven animals, and the clinical, hematological, biochemical, and gastroscopic parameters, as well as bleeding time, were evaluated in five timepoints and an electrocardiogram at three timepoints. No relevant adverse effects were observed in terms of the parameters evaluated. Significant differences were found in heart rate, AST and P wave duration, segmented neutrophils (%), and the levels of erythrocytes, hemoglobin, hematocrit, and MCH, compared with these parameters at T0; however, no animal manifested clinical alterations. Gastroscopy revealed discrete lesions (Grade 1) in the squamous gastric mucosa on day 14 of treatment in all animals; however, at the end of the study (day 28) these lesions had regressed to grade 0 in three of the horses and remained at grade 1 in the other four animals. Based on these results, we conclude that the use of meloxicam at a daily dose of 0.6 mg/kg, orally, for 28 consecutive days, did not cause relevant adverse effects in healthy horses.
长期服用美洛昔康对健康马匹的影响:临床、实验室、胃镜和心电图检查结果
非甾体抗炎药在兽医实践中被广泛使用。与非选择性抑制剂相比,COX-2 抑制剂被认为更安全;然而,有关其在马科动物中长期使用的研究却很少。本研究的目的是确定美洛昔康(COX-2 首选抑制剂)在健康马匹中可能产生的不良反应,口服剂量为 0.6 毫克/千克,每天一次,连续服用 28 天。对 7 匹马进行了配对试验,在 5 个时间点评估了临床、血液学、生物化学和胃镜参数以及出血时间,在 3 个时间点评估了心电图。在所评估的参数中未观察到相关的不良反应。与 T0 时的这些参数相比,心率、AST 和 P 波持续时间、分段中性粒细胞(%)以及红细胞、血红蛋白、血细胞比容和 MCH 的水平均有显著差异;但是,没有动物出现临床症状。胃镜检查显示,在治疗的第 14 天,所有动物的鳞状胃黏膜都出现了离散性病变(1 级);但在研究结束时(第 28 天),其中三匹马的病变已退至 0 级,另外四匹马的病变仍为 1 级。根据上述结果,我们得出结论:健康马匹连续 28 天口服美洛昔康(每日剂量为 0.6 毫克/千克)不会产生相关不良反应。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信